Sökning: WFRF:(Feresiadou A.) > Rapidly increasing ...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 04078naa a2200469 4500 | |
001 | oai:DiVA.org:uu-352681 | |
003 | SwePub | |
008 | 180607s2018 | |||||||||||000 ||eng| | |
009 | oai:DiVA.org:liu-151464 | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3526812 URI |
024 | 7 | a https://doi.org/10.1111/ane.129632 DOI |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-1514642 URI |
040 | a (SwePub)uud (SwePub)liu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Berntsson, Shala G.,d 1964-u Uppsala universitet,Neurologi,Uppsala Univ, Sweden4 aut0 (Swepub:uu)shabe360 |
245 | 1 0 | a Rapidly increasing off-label use of rituximab in multiple sclerosis in Sweden :b Outlier or predecessor? |
264 | c 2018-05-24 | |
264 | 1 | b Hindawi Limited,c 2018 |
338 | a print2 rdacarrier | |
500 | a Funding Agencies|County Council of Uppsala; Uppsala University | |
520 | a OBJECTIVES: Off-label use of rituximab to treat MS patients in Sweden is high, and the need for long-term safety data may not be met. Our objectives were to assess the rate of rituximab prescription in patients with multiple sclerosis in Sweden and, in addition, to evaluate the safety of rituximab in a single centre for patients with multiple sclerosis.MATERIAL AND METHODS: Review of the Swedish MS register was performed to study the number of MS patients treated with rituximab during the last 6 years. Investigation also included a retrospective review of medical files in search for possible side effects/adverse events in all adult patients with MS treated with rituximab at Uppsala University Hospital.RESULTS: Presently, in Sweden the rate of rituximab prescriptions in relation to other annually started of disease- modifying drugs in MS is 53.5%.CONCLUSIONS: The share of MS patients in Sweden who are treated with rituximab is very high, and also rapidly increasing. Taken into account the off-label use, cases with adverse medical conditions that could possibly be related to rituximab use should be reported thoroughly. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Neurologi0 (SwePub)302072 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Neurology0 (SwePub)302072 hsv//eng |
653 | a adverse events | |
653 | a immunomodulatory drugs | |
653 | a multiple sclerosis | |
653 | a off-label prescription | |
653 | a pharmacotherapy | |
653 | a rituximab side effects | |
700 | 1 | a Kristoffersson, Au Uppsala universitet,Neurologi,Neurology Policlinic, Department of Medical Specialist, Motala General Hospital, Motala, Sweden,Uppsala Univ, Sweden; Motala Gen Hosp, Sweden4 aut |
700 | 1 | a Boström, Ingeru Linköpings universitet,Avdelningen för neuro- och inflammationsvetenskap,Medicinska fakulteten,Region Östergötland, Neurologiska kliniken i Linköping4 aut0 (Swepub:liu)ingbo67 |
700 | 1 | a Feresiadou, Amaliau Uppsala universitet,Neurologi,Uppsala Univ, Sweden4 aut0 (Swepub:uu)amafe662 |
700 | 1 | a Burman, Joachim,d 1974-u Uppsala universitet,Neurologi,Uppsala Univ, Sweden4 aut0 (Swepub:uu)joabu293 |
700 | 1 | a Landtblom, Anne-Marieu Linköpings universitet,Uppsala universitet,Neurologi,Department of Clinical and Experimental Medicine, Neurology, Medical Faculty, University of Linköping, Linköping, Sweden; Neurology Policlinic, Department of Medical Specialist, Motala General Hospital, Motala, Sweden,Avdelningen för neuro- och inflammationsvetenskap,Medicinska fakulteten,Region Östergötland, Neurologiska kliniken i Linköping,Uppsala Univ, Sweden; Motala Gen Hosp, Sweden4 aut0 (Swepub:liu)annla55 |
710 | 2 | a Uppsala universitetb Neurologi4 org |
773 | 0 | t Acta Neurologica Scandinavicad : Hindawi Limitedg 138:4, s. 327-331q 138:4<327-331x 0001-6314x 1600-0404 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-352681 |
856 | 4 8 | u https://doi.org/10.1111/ane.12963 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-151464 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.